VIATRIS INC. Reclassification from AOCI, Current Period, Tax
VIATRIS INC. (VTRS) reported Reclassification from AOCI, Current Period, Tax of $9.60 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ReclassificationFromAociCurrentPeriodTax · last filed 2026-08-06
- VIATRIS INC. reclassification from aoci, current period, tax for the quarter ending 2026-06-30 was $9.60M.
- VIATRIS INC. reclassification from aoci, current period, tax for the quarter ending 2026-03-31 was $12.50M.
- VIATRIS INC. reclassification from aoci, current period, tax for the quarter ending 2025-12-31 was $3.40M, a 95.93% decline year-over-year.
- VIATRIS INC. reclassification from aoci, current period, tax for the quarter ending 2025-09-30 was $8.00M.
- VIATRIS INC. reclassification from aoci, current period, tax for fiscal 2025 was -$115.60M, a 245.41% decline from fiscal 2024.
- VIATRIS INC. reclassification from aoci, current period, tax for fiscal 2024 was $79.50M.
- VIATRIS INC. reclassification from aoci, current period, tax for fiscal 2023 was -$56.40M.
| Period end | Reclassification from AOCI, Current Period, Tax 3 month | Reclassification from AOCI, Current Period, Tax 6 month | Reclassification from AOCI, Current Period, Tax 9 month | Reclassification from AOCI, Current Period, Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.60M 10-Q · filed 2026-08-06 | $22.10M 10-Q · filed 2026-08-06 | $25.50M derived: sum of 3 quarters · filed 2026-08-06 | $33.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $12.50M 10-Q · filed 2026-05-07 | $15.90M derived: sum of 2 quarters · filed 2026-05-07 | $23.90M derived: sum of 3 quarters · filed 2026-05-07 | -$59.10M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $3.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $11.40M derived: sum of 2 quarters · filed 2026-02-26 | -$71.60M derived: sum of 3 quarters · filed 2026-08-06 | -$115.60M 10-K · filed 2026-02-26 |
| 2025-09-30 | $8.00M 10-Q · filed 2025-11-06 | -$75.00M derived: sum of 2 quarters · filed 2026-08-06 | -$119.00M 10-Q · filed 2025-11-06 | -$35.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$83.00M 10-Q · filed 2026-08-06 | -$127.00M 10-Q · filed 2026-08-06 | -$43.50M derived: sum of 3 quarters · filed 2026-08-06 | -$105.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$44.00M 10-Q · filed 2026-05-07 | $39.50M derived: sum of 2 quarters · filed 2026-05-07 | -$22.90M derived: sum of 3 quarters · filed 2026-05-07 | -$6.90M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $83.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $21.10M derived: sum of 2 quarters · filed 2026-02-26 | $37.10M derived: sum of 3 quarters · filed 2026-02-26 | $79.50M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$62.40M 10-Q · filed 2025-11-06 | -$46.40M derived: sum of 2 quarters · filed 2025-11-06 | -$4.00M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $16.00M 10-Q · filed 2025-08-07 | $58.40M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $42.40M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | -$56.40M 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |